News · 26 weeks21+450%
2026-03-012026-08-23
Mix1490d
- SEC Filings7(50%)
- Insider6(43%)
- Other1(7%)
Latest news
25 items- SECAmendment: Interpace Biosciences, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- INSIDERCEO, President & Chairman Burnell Thomas W. converted options into 1,966,763 shares and covered exercise/tax liability with 581,718 shares, increasing direct ownership by 1,954% to 1,455,927 units (SEC Form 4) to cover taxes4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- INSIDERSEC Form 4 filed by Director Aggarwal Vijay4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- INSIDERSEC Form 4 filed by Director Keegan Joseph D4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- INSIDERSEC Form 4 filed by Director Rocca Fortunato R.4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- INSIDERSEC Form 4 filed by Director Sullivan Stephen J4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- INSIDERCFO & COO Mccarthy Christopher converted options into 277,009 shares, increasing direct ownership by 592% to 323,800 units (SEC Form 4)4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECSEC Form 10-Q filed by Interpace Biosciences, Inc.10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- PRInterpace Biosciences Announces Second Quarter 2026 Financial and Business ResultsQ2 Revenue of $9.1 millionQ2 Income from Continuing Operations of $0.3 millionQ2 Thyroid volume year-over-year increase of 6%Q2 Thyroid revenue year-over-year increase of 9%Trailing twelve-month thyroid revenue of $36.1 million, an increase of 11% on a comparable thyroid-only basis PARSIPPANY, NJ, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the second quarter ended June 30, 2026 and provided a business and financial update. Interpace generated Q2 2026 revenue of $9.1 million on 9% year-over-year thyroid revenue growth, delivered $0.3 million of income from continuing operations or 3% of re
- SECSEC Form DEFA14A filed by Interpace Biosciences, Inc.DEFA14A - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECSEC Form DEF 14A filed by Interpace Biosciences, Inc.DEF 14A - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECSEC Form PRE 14A filed by Interpace Biosciences, Inc.PRE 14A - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECSEC Form 10-Q filed by Interpace Biosciences, Inc.10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- PRInterpace Biosciences Announces First Quarter 2026 Financial and Business ResultsQ1 Revenue of $9.0 millionQ1 Income from Continuing Operations of $0.8 millionQ1 Thyroid volume year-over-year increase of 10%Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update. Interpace generated Q1 2026 revenue of $9.0 million on 12% year-over-year thyroid revenue growth, delivered $0.8 million of income from continuing operations, and produced Adjusted EBITDA of $1.6 million, or 17% of revenue. "Our first quarter results demonstrate continued mo
- SECAmendment: SEC Form 10-K/A filed by Interpace Biosciences, Inc.10-K/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECSEC Form 10-K filed by Interpace Biosciences, Inc.10-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- PRInterpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business ResultsQ4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4 and FY Thyroid volume year-over-year increase of 11% and 13%Q4 and FY Thyroid revenue year-over-year increase of 14% and 21% PARSIPPANY, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided a business and financial update. Q4 and FY revenue were $9.2 million and $38.7 million, respectively. Q4 and FY income from continuing
- INSIDERLarge owner 1315 Capital Ii, L.P. converted options into 9,405,941 shares (SEC Form 4)4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- INSIDERLarge owner Ampersand 2018 Limited Partnership converted options into 13,861,386 shares (SEC Form 4)4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
IDXG FAQ
7 questionsWhat does Interpace Biosciences, Inc. do?
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that...Where does IDXG stock trade?
Interpace Biosciences, Inc. (IDXG) is listed on NASDAQ.What sector and industry is IDXG in?
Interpace Biosciences, Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Interpace Biosciences, Inc. go public?
Interpace Biosciences, Inc. (IDXG) completed its IPO in n/a.What are analysts saying about IDXG?
Interpace Biosciences, Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Neutral on 2021-11-17.What companies are similar to IDXG?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare IDXG side-by-side with any of them on Quantisnow.How can I track IDXG on Quantisnow?
Quantisnow aggregates Interpace Biosciences, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IDXG to receive live email and push alerts on every new disclosure.